A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
This trial compares two chemotherapy agents for the treatment of recurrent ovarian, fallopian
or primary peritoneal cancer in patients that have received and are no longer responding to
Platinum based treatment. The purpose of this trial is to compare progression free survival
between gemcitabine and liposomal doxorubicin. Progression free survival (PFS) is defined as
the period from study entry until disease progression